ATE213499T1 - Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose - Google Patents
Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen skleroseInfo
- Publication number
- ATE213499T1 ATE213499T1 AT95942842T AT95942842T ATE213499T1 AT E213499 T1 ATE213499 T1 AT E213499T1 AT 95942842 T AT95942842 T AT 95942842T AT 95942842 T AT95942842 T AT 95942842T AT E213499 T1 ATE213499 T1 AT E213499T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide analogues
- multiple sclerosis
- substitution
- treatment
- myelin protein
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102000006386 Myelin Proteins Human genes 0.000 title 1
- 108010083674 Myelin Proteins Proteins 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 title 1
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000054064 human MBP Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34207894A | 1994-11-18 | 1994-11-18 | |
| PCT/US1995/014402 WO1996016085A1 (en) | 1994-11-18 | 1995-11-16 | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE213499T1 true ATE213499T1 (de) | 2002-03-15 |
Family
ID=23340234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95942842T ATE213499T1 (de) | 1994-11-18 | 1995-11-16 | Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6369033B1 (de) |
| EP (2) | EP1172376A1 (de) |
| JP (1) | JPH10509714A (de) |
| AT (1) | ATE213499T1 (de) |
| AU (1) | AU721898B2 (de) |
| CA (1) | CA2205532A1 (de) |
| DE (1) | DE69525544T2 (de) |
| MX (1) | MX9703642A (de) |
| WO (1) | WO1996016085A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7090982B2 (en) | 1991-10-22 | 2006-08-15 | The Governors Of The University Of Alberta | Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient |
| US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| CA2133749A1 (en) * | 1992-04-09 | 1993-10-28 | Howard L. Weiner | Suppression of t-cell proliferation using peptide fragments of myelin basic protein |
| IL115766A0 (en) * | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
| US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| EP1172376A1 (de) * | 1994-11-18 | 2002-01-16 | Neurocrine Biosciences, Inc. | Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose |
| US6251396B1 (en) * | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| WO1996028470A2 (en) * | 1995-03-09 | 1996-09-19 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
| WO1997030150A2 (en) * | 1996-02-15 | 1997-08-21 | Pangenetics B.V. | Molecules for the induction of immunological tolerance |
| US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| US6541608B1 (en) * | 1999-02-23 | 2003-04-01 | Baylor College Of Medicine | T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
| CA2445640A1 (en) * | 2001-03-23 | 2002-10-03 | John Matsoukas | Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms) |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| WO2004015070A2 (en) * | 2002-08-08 | 2004-02-19 | Baylor College Of Medicine | Isolation and identification of t cells |
| CA2605321A1 (en) | 2005-04-19 | 2006-10-26 | Eli Lilly And Company | Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
| PT2016414E (pt) * | 2006-05-05 | 2015-11-24 | Opexa Therapeutics | Vacina de células t |
| CN102317316B (zh) | 2008-12-19 | 2014-08-13 | 帕尼玛制药股份公司 | 人抗α突触核蛋白自身抗体 |
| US20140348861A1 (en) | 2011-05-05 | 2014-11-27 | National Institute Of Immunology | Synthetic peptides and random copolymers for the treatment of autoimmune disorders |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| CN103102393B (zh) * | 2013-01-30 | 2015-01-07 | 北京大学 | 一种多肽及其在制备抑郁症治疗药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
| AU651097B2 (en) * | 1990-03-02 | 1994-07-14 | Autoimmune, Inc. | Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens |
| US6077509A (en) * | 1990-03-30 | 2000-06-20 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
| ES2144418T3 (es) * | 1991-05-31 | 2000-06-16 | Connetics Corp | Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario. |
| CA2053799C (en) * | 1991-10-22 | 2002-03-12 | Kenneth G. Warren | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
| CA2133749A1 (en) * | 1992-04-09 | 1993-10-28 | Howard L. Weiner | Suppression of t-cell proliferation using peptide fragments of myelin basic protein |
| EP0720622A1 (de) * | 1993-09-22 | 1996-07-10 | The Board Of Trustees Of The Leland Stanford Junior University | Wechselwirkung zwischen t-zellrezeptoren und antigen in autoimmunkrankheiten |
| US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| EP1172376A1 (de) * | 1994-11-18 | 2002-01-16 | Neurocrine Biosciences, Inc. | Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose |
-
1995
- 1995-11-16 EP EP01115315A patent/EP1172376A1/de not_active Withdrawn
- 1995-11-16 DE DE69525544T patent/DE69525544T2/de not_active Expired - Fee Related
- 1995-11-16 WO PCT/US1995/014402 patent/WO1996016085A1/en not_active Ceased
- 1995-11-16 AT AT95942842T patent/ATE213499T1/de not_active IP Right Cessation
- 1995-11-16 AU AU44057/96A patent/AU721898B2/en not_active Ceased
- 1995-11-16 JP JP8516910A patent/JPH10509714A/ja not_active Ceased
- 1995-11-16 EP EP95942842A patent/EP0792286B1/de not_active Expired - Lifetime
- 1995-11-16 CA CA002205532A patent/CA2205532A1/en not_active Abandoned
-
1997
- 1997-05-16 MX MX9703642A patent/MX9703642A/es not_active Application Discontinuation
- 1997-10-20 US US08/953,937 patent/US6369033B1/en not_active Expired - Fee Related
-
2001
- 2001-11-19 US US09/989,476 patent/US6489299B2/en not_active Expired - Fee Related
-
2002
- 2002-10-11 US US10/270,707 patent/US6740638B2/en not_active Expired - Fee Related
-
2004
- 2004-04-08 US US10/820,983 patent/US20040214775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69525544T2 (de) | 2002-08-22 |
| EP0792286A1 (de) | 1997-09-03 |
| AU721898B2 (en) | 2000-07-20 |
| US20020058627A1 (en) | 2002-05-16 |
| US6369033B1 (en) | 2002-04-09 |
| AU4405796A (en) | 1996-06-17 |
| DE69525544D1 (de) | 2002-03-28 |
| JPH10509714A (ja) | 1998-09-22 |
| EP1172376A1 (de) | 2002-01-16 |
| WO1996016085A1 (en) | 1996-05-30 |
| CA2205532A1 (en) | 1996-05-30 |
| US20030114380A1 (en) | 2003-06-19 |
| MX9703642A (es) | 1998-11-29 |
| EP0792286B1 (de) | 2002-02-20 |
| US6740638B2 (en) | 2004-05-25 |
| US6489299B2 (en) | 2002-12-03 |
| US20040214775A1 (en) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE213499T1 (de) | Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose | |
| ATE266043T1 (de) | Peptidanaloge des menschlichen basischen myelinproteins | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| DE3585556D1 (de) | Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten. | |
| ATE230797T1 (de) | Stabile produkte des bakterientötenden/durchlässigkeiterhöhenden proteins (pbi) und diese enthaltende arzneimittelzusammensetzungen | |
| ATE108662T1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
| DE3852636D1 (de) | Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2). | |
| IL109403A0 (en) | Oral drug delivery compositions and methods | |
| FI860153A0 (fi) | Oligopeptider, deras mellanprodukter och foerfarande foer deras framstaellning. | |
| WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
| ATE377026T1 (de) | Behandlung von fettleibigkeit | |
| DE3483931D1 (de) | Wachstumshormone freisetzende peptiden und methode fuer die behandlung von saeugetieren. | |
| BG97123A (bg) | Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа | |
| ATE3416T1 (de) | Pharmakologisch aktive peptide und diese enthaltende arzneimittel. | |
| DE69430416D1 (de) | Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen | |
| GR3001922T3 (en) | Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration | |
| DE69102069D1 (de) | 5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen. | |
| ATE92078T1 (de) | Pharmakologisch aktive peptide. | |
| DE3162674D1 (en) | A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it | |
| KR920700224A (ko) | 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제 | |
| ATE27822T1 (de) | Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus. | |
| KR950704358A (ko) | 카텝신 l 특이적 저해 폴리펩티드 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |